Celltrion Healthcare’s Yuflyma®, Biosimilar To AbbVie’s Humira® (Adalimumab), Now Available In 80mg Auto-Injector And Pre-Filled Syringe

Aug 30, 2023

Celltrion Healthcare Canada announced that Yuflyma®, biosimilar to AbbVie’s Humira® (adalimumab), is now available in an 80 mg auto-injector and pre-filled syringe. It is the only adalimumab biosimilar available at an 80 mg dose in an auto-injector.

On 1 July 2023, Yuflyma® became commercially available in the US after Celltrion obtained a licence from AbbVie on 27 April 2022.

Print Page Mail Article